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Identification and characterization of bisbenzimide compounds
that inhibit human cytomegalovirus replication
Nicole Falci Finardi1†, HyeongJun Kim2,3, Lee Z. Hernandez2,3,4, Matthew R. G. Russell5, Catherine M-K Ho1, Vattipally
B. Sreenu6, Hannah A. Wenham1, Andy Merritt7 and Blair L. Strang1,8,*,†

Abstract
The shortcomings of current anti-human cytomegalovirus (HCMV) drugs has stimulated a search for anti-HCMV compounds
with novel targets. We screened collections of bioactive compounds and identified a range of compounds with the potential to
inhibit HCMV replication. Of these compounds, we selected bisbenzimide compound RO-90-7501 for further study. We generated analogues of RO-90-7501 and found that one compound, MRT00210423, had increased anti-HCMV activity compared to
RO-90-7501. Using a combination of compound analogues, microscopy and biochemical assays we found RO-90-7501 and
MRT00210423 interacted with DNA. In single molecule microscopy experiments we found RO-90-7501, but not MRT00210423,
was able to compact DNA, suggesting that compaction of DNA was non-obligatory for anti-HCMV effects. Using bioinformatics
analysis, we found that there were many putative bisbenzimide binding sites in the HCMV DNA genome. However, using western
blotting, quantitative PCR and electron microscopy, we found that at a concentration able to inhibit HCMV replication our compounds had little or no effect on production of certain HCMV proteins or DNA synthesis, but did have a notable inhibitory effect
on HCMV capsid production. We reasoned that these effects may have involved binding of our compounds to the HCMV genome
and/or host cell chromatin. Therefore, our data expand our understanding of compounds with anti-HCMV activity and suggest
targeting of DNA with bisbenzimide compounds may be a useful anti-HCMV strategy.

novel anti-HCMV drugs targeting UL97, or DNA packaging complex proteins, also have significant issues with the
development of antiviral resistance [7–12] or are thought to
have poor efficacy in clinical trials [13, 14]. To overcome the
development of antiviral resistance when targeting proteins
expressed by HCMV, there has been interest in inhibiting the
function of cellular proteins required for HCMV replication.
The stability of the cellular genome would limit the occurrence of mutations that would allow anti-viral resistance to
occur.

INTRODUCTION
Disease caused by human cytomegalovirus (HCMV) is wide
ranging and has significant social and economic impact [1].
Currently, there is no widely available vaccine against HCMV
[1, 2]. Plus, the use of first- and second-line antiviral drugs
inhibiting the HCMV DNA polymerase (ganciclovir and
foscarnet) have a number of shortcomings, including the
development of antiviral resistance [3].
The identification of novel anti-HCMV drugs [4, 5] has
focused on finding compounds that inhibit the function of
a limited number of HCMV proteins, including the HCMV
kinase UL97 and the HCMV DNA packaging complex
proteins [5, 6]. However, like ganciclovir and foscarnet,

A number of cellular proteins required for HCMV replication have been identified [15] and there have been efforts to
identify compounds known to inhibit the function of cellular
proteins required for anti-HCMV replication (some examples
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of which can be found in the literature [16–22]). However,
none of the compounds identified in the aforementioned
works have progressed toward clinical development due to
a number of factors, for example polypharmacology of the
compounds identified.

synthesized MRT00210423, MRT00210424, MRT00210425,
MRT00210426 and MRT00210427 using the schemes shown
in Fig. S1 (available in the online version of this article). All
compounds were resuspended in DMSO.

Viral yield reduction assays
Assays were performed essentially as described previously
[26]. HFF cells were plated at 5×104 cells per well in 24-well
plates. After overnight incubation, cells were infected with
HCMV at an m.o.i. of 1. After virus adsorption for 1 h at
37 °C, cells were washed and incubated with 0.5 ml of media
containing DMSO or compounds at a range of concentrations. Plates were incubated for 4 days at 37 °C. Titres were
determined by serial dilution of viral supernatant onto HFF
monolayers which were covered in DMEM containing 5 %
FBS, 0.6 % methylcellulose and antibiotics. Cultures were
incubated for 14 days, cells were stained with crystal violet
and plaques were counted. The final concentration of DMSO
in all samples was maintained at <1 % (v/v). The EC50 value of
data from this assay was calculated using GraphPad.

Novel strategies for inhibition of HCMV replication need to
be explored. To this end, we decided to screen compounds
with known bioactive activity for anti-HCMV activity.

METHODS
Cells and viruses
Human foreskin fibroblast (HFF) cells (clone Hs29) were
obtained from American Type Culture Collection no. CRL-
1684 (ATCC). All cells were maintained in complete media:
Dulbecco’s modified Eagle medium (DMEM) containing 10 %
FBS, plus penicillin and streptomycin (all Gibco). HCMV
strains AD169 and Merlin(R1111) were kindly provided by
Don Coen (Harvard Medical School) and Richard Stanton
(Cardiff University), respectively.

MTT cytotoxicity assays
Assays were performed essentially as described [26]. In this
colorimetric assay the ability of cellular NAD(P)H-dependent
cellular oxidoreductase enzymes to reduce the tetrazolium
dye 3-(4,5-dimethylthiazol-2-yl)−2,5-diphenyltetrazolium
bromide (MTT) to formazan was measured. HFF cells were
seeded at 1×104 or 1×103 cells per well into 96-well plates.
High concentrations of cells (1×104 per well) should allow
assessment of cell viability, whereas low concentrations of
cells (1×103 per well) should allow assessment of both cell
viability and cell proliferation. After overnight incubation to
allow cell attachment, cells were treated for 96 h with a range
of concentrations of compound, or the equivalent volume
of DMSO. MTT assays were then performed according to
the manufacturer’s instructions (GE Healthcare). The final
concentration of DMSO in all samples was maintained at <1 %
(v/v).

Compound collections
The Microsource-1 US Drug Collection (Discover Systems)
contained compounds that had reached clinical trial stage
in the USA. LOPAC 1 (Sigma-Aldrich) contained known
pharmacologically active compounds. NIH Clinical Collection (BioFocus) comprised the 2012 versions of compound
collections NCC1 and NCC2, which contained compounds
that had a history of use in clinical trials. All compounds were
resuspended in DMSO (stock solution concentrations for each
collection were 2 mg ml−1, 10 mM and 10 mM, respectively).
High-throughput screening of compounds
We have previously described infection of HFF cells with
HCMV strain AD169 for high-throughput screening, preparation of screening plates for high-throughput microscopy
analysis, microscopy analysis of screening plates and analysis
of screening results in several works describing screening
small molecules and small interfering RNA (siRNA) collections [20–23]. The experimental methodology is described in
the results section. The final amount of each compound in the
screening assay was: Microscource – 200 ng, LOPAC – 28 µM,
NIH – 28 µM.

Light microscopy
HFF cells were seeded in 24-
well tissue culture plates
(5×104 cells per well). Twenty-four hours later, cells were
treated with the concentrations of compound indicated in the
text or the equivalent volume of DMSO in complete media.
After 1 h of incubation with compounds or DMSO at 37 °C,
cells were placed at room temperature followed by incubation
with ice cold methanol (30 min). Cells were washed with PBS
and imaged using a Zeiss Axioplan 2 microscope.

To assess the quality of data that could be returned from
the screening protocol, we calculated the Z’-factor [24, 25]
derived from the positive (heparan sulphate-treated infected
cells) and negative (DMSO-treated infected cells) control
wells. The screening controls for one plate in the LOPAC
collection returned Z’-factors of <0.5. Thus, the data from
that plate were discarded. All other screening plates returned
Z’-factors ≥0.5, indicating a robust separation of difference in
the data derived from positive and negative controls.

Agarose gel electrophoresis
Plasmid pUC19 (a kind gift from Steve Goodbourn, St
George’s, University of London) was linearized by digestion with enzyme EcoRI using the supplier’s (New England
Biolabs) instructions. A 0.8 % TAE agarose gel was prepared
with compound added to a concentration of 10 µM and
the linearized plasmid was introduced into the gel via electrophoresis. Also introduced into the gel was a ladder of

Compounds
RO-90-7501
(2′-(4-aminophenyl)-[2,5′-bi-1H-benzi
midazol]−5-
amine) was purchased from Tocris. We
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cell through biotin–neutravidin interaction) was prepared
as previously described elsewhere [27]. Briefly, lambda
DNA had 12 nt overhangs at both ends. Biotin-labelled
(5′-aggtcgccgccc/3′BioTEG/-3′)
and
digoxigenin
(5′-gggcggcgacctaaaaaaaaaaaa/3′Dig_N)-labelled
oligos
complementary to the overhangs were annealed and ligated
to lambda DNA. The ligation reaction mixture was run on a
0.4 % agarose gel, allowing unconjugated excess oligos to be
separated from labelled DNA by electrophoresis. The DNA
band corresponding to the biotin- and digoxigenin-labelled
lambda DNA was excised from the gel. The purified biotinand digoxigenin-labelled lambda DNA was recovered from
the excised agarose gel in a dialysis bag and concentrated
using an ethanol precipitation of DNA procedure.

Preparation of a flow cell for single-molecule
microscopy flow-stretching assays
A microfluidic flow cell was assembled using a quartz top,
a surface-passivated cover glass (using polyethylene glycol),
double-sided tape, and inlet and outlet tubes as previously
described elsewhere [27, 28]. Approximately 4 % of the polyethylene glycol layer on the cover glass had biotin moieties
onto which were tethered the dual labelled lambda DNAs
described above. To fix the dual labelled lambda DNA to
the glass cover, 0.25 mg ml−1 neutravidin was added to the
flow cell and incubated for at least 5 min. The excess neutravidin was removed by flowing Qdot-labelling buffer (10 mM
Tris, pH 8.0, 150 mM NaCl, 10 mM MgCl2, 0.2 mg ml−1
BSA) into the flow cell. Then, the biotin- and digoxigenin-
labelled lambda DNA was flowed into the flow cell at a rate
of 30 µl min−1. Excess dual labelled DNAs not joined to the
cover glass surface were removed by flowing in Qdot-labelling
buffer. Quantum dots were affixed to DNA by flowing 250 µl
of 750-fold diluted anti-digoxigenin-conjugated quantum
dot 605 (Thermo Fisher Scientific S10469, anti-digoxigenin
antibody: GeneTex GTX73152) at a rate of 30 µl min−1. The
flow cell was washed to remove the excess quantum dots by
flowing imaging buffer (20 mM Tris, pH 7.5, 150 mM NaCl,
2 mM MgCl2, 1.2 mg ml−1 BSA) into the flow cell at a rate of
50 µl min−1.

Fig. 1. Compounds assigned z-scores. The ability of compounds within
the NIH Clinical, Microsource and LOPAC collections to inhibit HCMV
strain AD169 pp28 protein production in HFF cells was investigated.
After exclusion of compounds judged to be cytotoxic, each compound
was assigned a z-score (the number of standard deviations from the
mean value of the screen) to describe the number of cells expressing the
HCMV antigen pp28. Thus, negative and positive z-scores represented
fewer or greater numbers of cells expressing pp28, respectively.
A plot of all z-scores is shown for each collection, where each data
point represents a single compound. Lists of compounds from each
collection with their assigned z-scores are shown in Tables S4-S6. The
z-scores of RO-90-7501, PMEG and valaciclovir are indicated with red
arrows. The structure of RO-90-7501 is also shown.

DNA markers (N3232S; New England Biolabs). The gel was
exposed to UV light and images of the gel were captured using
a Syngene camera apparatus.

Analysis of putative binding sites in the HCMV
genome
The complete analysis pipeline along with the source code is
available on the GitHub page (https://github.com/vbsreenu/
find-motif). Briefly, genome sequences in fasta format and
gene features in gff format were downloaded from GenBank
with the help of NCBI’s eutils API (scripts are available on
GitHub: https://github.com/vbsreenu/find-motif). Using
a custom FIND_MOTIF program, nucleotide motifs were
extracted from genome sequence files and their corresponding gene features from the gff file. The FIND_MOTIF
program was developed in C programming language using
a Karp-Robin string search algorithm to find nucleotide
motifs (kmers) in the genome sequence file. The locations of
the motifs were then compared with a genome features table
file using an AWK script to find whether the motifs were part
of any coding region. Final results were stored in a specified
output file.

Data capture and analysis in single-molecule DNA
flow-stretching assays
Each compound was diluted in imaging buffer containing
BSA at the concentrations mentioned in the text. Compound
or DMSO were flowed into the cell at a rate of 50 µl min−1.
Quantum dots labelled on lambda DNA were imaged under a
total internal reflection fluorescence microscope with 532 nm
laser illumination. Movement of quantum dots (Lamdba DNA
compaction events) were recorded using Micro-Manager
software [29] and, subsequently, kymographs were prepared
using ImageJ [30].

Dual labeling of bacteriophage lambda genomic
DNA for single-molecule microscopy
Bacteriophage lambda genomic DNA (lambda DNA) with
a digoxigenin moiety at one terminus (to label DNA with
a quantum dot) and a biotin moiety at the other terminus
(to tether the DNA onto the surface of a microfluidic flow

Western blotting
HFF cells (5×104 cells per well) were infected with virus
(m.o.i. 1) and treated with the concentrations of compounds
indicated in the text or the equivalent volume of DMSO.
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Table 1. Compounds assigned low z-scores in the screening assay
Compound

ChEMBL ID

Library

z-score

AM-251

CHEMBL285932

NIH Clinical Collection

−2.1

Ancitabine HCl

CHEMBL1412614

LOPAC

−3.0

Aurintricarboxylic acid

CHEMBL275938

LOPAC

−3.6

LOPAC

−2.1

S-(p-Azidophenacyl) glutathione

 

–

Carboplatin

CHEMBL1351

Microscource

−5.1

Cetirizine HCl

CHEMBL1000

Microscource

−2.1

Chloroxylenol

CHEMBL398440

Microscource

−2.1

CHEMBL452

Microscource

−2.2

Clopidol

CHEMBL446918

Microscource

−2.1

Dibenzothiophene

CHEMBL219828

Microscource

−2.0

Floxuridine

CHEMBL917

NIH Clinical Collection

−3.5

Fludarabine

CHEMBL1568

NIH Clinical Collection

−3.2

Hexachlorophene

CHEMBL496

NIH Clinical Collection

−4.9

CHEMBL443605

Microscource

−2.0

Lisinopril

CHEMBL1237

Microscource

−2.1

Methotrexate

CHEMBL426

Microscource

−2.9

CHEMBL20283

LOPAC

−5.4

CHEMBL36

Microscource

−2.1

Raltitrexed

CHEMBL225071

NIH Clinical Collection

−3.0

Ranolazine

CHEMBL1404

Microscource

−2.2

Rifaximin

CHEMBL1617

Microscource

−2.3

RO-90-7501

–

LOPAC

−3.8

Salicylanilide

CHEMBL82970

Microscource

−2.0

Tamoxifen

CHEMBL83

Microscource

−2.5

Tenoxicam

CHEMBL302795

Microscource

−2.6

Unknown

–

NIH Clinical Collection

−2.4

CHEMBL312448

Microscource

−2.1

Clonazepam

Hexylresorcinol

PMEG
Pyrimethamine

Xylometazoline HCl





All samples were prepared for western blotting by washing
cells once in PBS, then suspending cells directly in 50 µl
2× Laemmli buffer containing 5 % β-mercaptoethanol
before incubating at 95 °C for 5 min. Western blotting of
proteins was carried out as described elsewhere [31], using
antibodies recognizing IE1/2, UL57, pp28, (all Virusys,
1 : 1000 dilution), UL86 (a kind gift from Wade Gibson,
Johns Hopkins School of Medicine, 1 : 1000 dilution) and
β-actin (Sigma, 1 : 5000 dilution). All primary antibodies
were incubated overnight at 4 °C and detected using an
anti-mouse- or anti-rabbit-HRP-conjugated antibody

(New England Biolabs). Chemiluminescence solution (GE
Healthcare) was used to detect secondary antibodies on
film.

Real time quantitative PCR analysis of viral DNA
synthesis in HCMV-infected cells
Preparation of samples for PCR and PCR analysis were
conducted using the methodology and reagents we have
described elsewhere [23, 32, 33] to calculate the number of
copies of the viral gene UL83 per copy of the cellular gene
adipsin. Statistical analysis was performed using Graphpad.
4
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Fig. 2. Structure of bisbenzimide compounds. (a) The structure of Hoechst 33258. The binding of Hoechst 33258 to DNA via hydrogen
bonds between amine groups in Hoechst 33258 and oxygen and nitrogen atoms in adenine and thymine nucleotides [40] is indicated
with red dotted lines. (b) The structure of RO-90-7501; the predicted binding of this compound to DNA via hydrogen bonding is indicated
by red dotted lines.

in the NIH Clinical, Microsource and LOPAC collections for
potential anti-HCMV activity. Briefly, cells infected with the
high-passage HCMV strain AD169 [35] were treated with
compounds from each collection. Two factors were then
assayed using automated microscopy: the number of cells
in each well and the number of cells expressing the HCMV
antigen pp28. pp28 is essential for HCMV replication [36] and
its expression late in HCMV replication is dependent on viral
DNA synthesis [37]. Therefore, our screen had the potential
to identify compounds able to inhibit several stages of HCMV
replication, including viral DNA synthesis. Those compounds
that produced a decrease in the number of cells in the assay
by 50 % or greater were judged to be cytotoxic to HCMV-
infected cells (Tables S1–S3) and were not studied further.
The remaining data from the screen were then converted to
a z-score (the number of standard deviations from the mean
of the data [24, 25]) to show an increase or decrease in the
number of cells expressing pp28 (positive or negative z-score,
respectively) (Fig. 1, Tables S4–S6).

Electron microscopy analysis of HCMV-infected
cells
HCMV-infected HFF cells were treated as outlined in the
figure legends. To prepare cells for analysis, cells were incubated for 1 h at room temperature in fixative (1.5 % glutaraldehyde and 4 % paraformaldehyde in 0.1 M sodium cacodylate
buffer, pH 7.4). After fixation, cells were washed three times
for 15 min in 0.1 M sodium phosphate buffer (pH 7.4) and
dehydrated in ethanol (50, 70, 90%, 15 min wash each). Cells
were then washed in 90 % ethanol containing LR-White
embedding medium (2 h) and transferred to gelatin capsules
(polymerization at 55 °C for 24 h).
Eighty-nanometre sections of each capsule were stained
with lead citrate and imaged in a 1400 FLASH transmission
electron microscope (JEOL) at −2 µm defocus with 2.8 nm
pixels using 2×2 TEM centre montaging. Montages were
then converted to mrc format and contrast adjusted, before
outputting as a 1 : 1 tif series with the ‘movie’ function, using
the tif2mrc and 3dmod packages of IMOD [34].

We investigated if our screening results were consistent
with the activity of known antiviral compounds and data
previously reported using these compound collections. We
noted that one antiviral compound with known anti-HCMV
activity, PMEG [38], was assigned a negative z-score (−5.4;
Fig. 1, Table S6), while an antiviral compound known to have
poor anti-HCMV activity, valaciclovir [39], was assigned a
z-score close to zero (0.4; Fig. 1, Table S4). Therefore, our

RESULTS
Screening of bioactive compound collections
We have previously employed an automated high-throughput
screening methodology to identify compounds and siRNAs
with potential anti-HCMV activity [20–23]. We used this
methodology to screen collections of bioactive compounds
5
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screening data were consistent with the known anti-HCMV
activity of at least two compounds.

experiment has reported the same findings as our screens.
Therefore, the compounds we identified in our screen may
have had a specific anti-HCMV activity and were unlikely to
be identified due an unappreciated non-specific activity of
the compound.

To our knowledge, the NIH Clinical Collection used here
has not been previously used to identify compounds with
anti-HCMV activity. The Microsource collection has been
used in screening experiments to identify compounds with
anti-HCMV activity [16–18]. However, these screens had
different parameters to our own (inhibition of ectopic GFP
expression controlled by viral protein IE2 [16], inhibition
of IE2-YFP fusion protein expression from a recombinant
HCMV virus [17] and inhibition of fusion protein pp28-GFP
expression from a recombinant HCMV virus [18]) and,
therefore, reported considerably different results. Screening
of the LOPAC collection for anti-HCMV activity using an
assay different to our own has been reported [19], but the
screening methodology and the full list of compounds with
anti-HCMV activity found in the aforementioned screen
have not been reported [19]. Therefore, it was not possible to
compare our data with the previously reported screen of the
LOPAC collection.

The compounds assigned low z-scores (less than −2.0) in each
collection were examined further (Table 1). A wide range of
compounds were found to inhibit the expression of pp28 in
our assay. Expression of pp28 is dependent on viral DNA
synthesis [37], which was consistent with compounds known
to inhibit viral DNA synthesis (PMEG) being assigned the
lowest z-scores (Table 1). However, it was unclear or unknown
how a number of other compounds assigned low z-scores
(including aurintricarboxylic acid, floxuridine, fludarabine
or hexachlorophene; Table 1) affected pp28 expression.
We then decided to choose a compound in Table 1 for further
investigation. We sought a compound that had a low z-score,
had not previously been reported to inhibit HCMV, may have
had a target other than a viral or cellular protein, and could be
amenable to modification. Based on these criteria, we chose
to investigate how RO-90-7501 (Fig. 1) might inhibit HCMV
replication.

We also considered whether some compounds were routinely
identified in a range of screens due to an unappreciated non-
specific effect of the compound. All three compound collections examined here have been used in a range of screens,
some mentioned above. To our knowledge, no other screening

To our knowledge, there were no previous reports that
RO-90-7501 could inhibit HCMV replication. RO-90-7501 is

Fig. 3. Anti-HCMV activity of RO-90-7501 analogues. HFF cells were infected with HCMV strain AD169 (m.o.i. 1) in the presence of the
compounds indicated in the figure (1 µM) or the equivalent volume of DMSO. At 96 h post-infection, virus titre (p.f.u. ml–1) from these
infections was determined. The data points from three independent experiments are shown. The columns and error bars represent the
mean and sd, respectively, of those data points. The structures of the bisbenzimide compounds examined are shown to the right of the
figure. Amine groups thought to be involved in DNA binding in each compound are highlighted in red text. Terminal amine groups of the
compounds are highlighted in green boxes.

6

Falci Finardi et al., Journal of General Virology 2021;102:001702

a bisbenzimide compound and structurally similar to other
well-known bisbenzimide compounds that bind DNA, such as
the so-called ‘Hoechst dyes’, which bind in the minor groove of
the DNA helix via interactions with adenine–thymine base pairs
[40] and fluoresce upon exposure to UV light. A comparison
of RO-90-7501's structure with that of a well-characterized
Hoechst dye, Hoechst 33258, is shown in Fig. 2. Also indicated
in Fig. 2 is the mechanism by which Hoechst 33258 binds to
DNA, principally through hydrogen bonds between amine
groups in the Hoechst 33258 compound and groups within
purine bases of the minor groove of DNA [40] (red dotted
lines, Fig. 2a) [40]. As RO-90-7501 had the essential structure
required for DNA binding [40], we hypothesized that RO-90-
7501 could interact with DNA using the same mechanism as
Hoechst 33258 (red dotted lines, Fig. 2b). To our knowledge,
there were no previous reports of HCMV replication inhibition
by bisbenzimide compounds or any other compound known to
bind to the minor groove of the DNA helix.
Before continuing further, we were concerned that bisbenzimide
compounds may have off-target effects that affect cell viability in
cell culture experiments or in vivo, probably due to their ability
to bind DNA. However, it had been reported that Hoechst 33342
could inhibit poxvirus replication in cell culture experiments
with no obvious cellular toxicity [41]. In addition, Hoechst
33342 has been administered to mice with no obvious adverse
effects [42] and the bisbenzimide compound pibenzimol has
been administered to humans without obvious adverse effects
[43]. Therefore, we speculated that RO-90-7501 and similar
compounds may not have off-target effects that would obviously
limit their use in cell culture or in vivo.

Identification of RO-90-7501 analogues with antiHCMV activity
Modification of compound structure can often reveal novel
compounds with enhanced antiviral activity. Therefore, to
find novel compounds with anti-HCMV activity, we generated
compounds structurally related to RO-90-7501 (Fig. 3). As
DNA binding is likely to be essential for the antiviral activity
of RO-90-7501, we decided that any compounds we generated must contain the amine groups within RO-90-7501 that
are likely to be required for DNA binding (highlighted in red,
Fig. 3). It was unknown what, if any, effect the amine groups at
the termini of RO-90-7501 had on anti-HCMV activity (highlighted in green, Fig. 3). Therefore, we focused on modifying
the termini of RO-90-7501. We generated compounds that did
not possess either of the terminal amine groups (MRT00210425
and MRT00210424) and a compound that had neither of the
terminal amine groups (MRT00210423) (Fig. 3).

Fig. 4. Virus replication and toxicity in the presence of RO-90-7501 or
MRT00210423. HFF cells were infected with HCMV strain (a) AD169
or (b) Merlin(R1111) and then treated with the concentrations of RO-
90-7501 or MRT00210423 indicated in the figure or the corresponding
volume of DMSO. Virus production at 96 h post-infection is shown as
the percentage of infectious virus in the presence of RO-90-7501 or
MRT00210423 compared to the appropriate DMSO control. The titre of
the viruses analysed in these figures is shown in Fig. S2. (c, d) A high and
low concentration of HFF cells (respectively, see Methods) were treated
for 96 h with the concentrations of RO-
90-
7501 or MRT00210423
indicated in the figure or the corresponding volume of DMSO and then
examined using an MTT assay. The data points and error bars in each
panel represent the mean of three independent experiments and the sd
of those experiments, respectively. At some data points, the error bars
are too small to be represented on the figure.

We compared the antiviral activity of these compounds to
that of RO-
90-
7501 and DMSO (Fig. 3). MRT00210425,
MRT00210424 and MRT00210423 all had anti-HCMV activity
greater than that of RO-90-7501. Loss of either terminal amino
group of RO-90-7501 (MRT00210425 and MRT00210424) had
a moderately greater antiviral effect compared to RO-90-7501,
whereas loss of both terminal amino groups (MRT00210423)
showed the greatest antiviral effect compared to RO-90-7501.
7
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We decided to focus our efforts on studying the antiviral effects
of MRT00210423 compared to RO-90-7501.

dose-dependent decrease in HCMV production in the presence of both RO-90-7501 and MRT00210423, indicating that
both compounds were able to inhibit AD169 replication.
The 50 % effective concentration (EC50) values of RO-90-
7501 and MRT00210423 were calculated as 1.2 and 0.3 µM
respectively. Consistent with the data shown in Fig. 3, the
EC50 value of MRT00210423 was greater than that of RO-90-
7501. We found similar results when we assayed the ability of
RO-90-7501 to inhibit replication of the low-passage HCMV
strain Merlin (Fig. 4b), whose genetic content was similar
to wild-type strains of HCMV [35] (EC50 of 2.6 and 0.5 µM
for RO-90-7501 and MRT00210423, respectively). Therefore, RO-90-7501 and MRT00210423 could inhibit HCMV
replication and could do so at EC50 concentrations similar
to those reported for the current frontline anti-HCMV drug
ganciclovir [26, 44].

Investigation of RO-90-7501 and MRT00210423
anti-HCMV activity
To confirm that RO-90-7501 and MRT00210423 could
inhibit HCMV replication, a virus yield reduction assay
was used to compare the production of HCMV strain
AD169 in the presence of increasing concentrations of
RO-90-7501, MRT00210423 or DMSO (Fig. 4a). We found a

We then used an MTT assay to assess the viability of a high
concentration of uninfected cells treated with increasing
concentrations of DMSO or RO-90-7501 (Fig. 4c). The 50 %
cellular toxicity concentration (CC50) of both compounds
was in excess of 10 µM, considerably greater than the EC50
values observed in Fig. 4(a). We also performed this assay
with a low concentration of uninfected cells to assess both
cell viability and proliferation (Fig. 4d). The CC50 concentration of both compounds was in excess of 10 µM. Therefore,
treatment of cells with RO-90-7501 or MRT00210423 had
no obvious toxic effect in either assay, and the inhibition of
virus replication observed in our virus yield reduction assays
(Fig. 4a, b) was unlikely to be due to toxic effects of either
RO-90-7501 or MRT00210423.

Investigation of compound association with DNA
To confirm that RO-90-7501 and MRT00210423 could associate with DNA, we used light microscopy to understand if,
like Hoechst compounds, RO-90-7501 and MRT00210423
could associate with host cell chromatin in uninfected
cells. HFF cells were treated with either RO-
90-
7501,
MRT00210423 or DMSO. Upon exposure to UV light, host
cell chromatin could be visualized in cells treated with both
RO-90-7501 and MRT00210423 (Fig. 5), suggesting that
RO-90-7501 was associated with host cell chromatin. We
noted that visualization of chromatin in cells treated with
MRT00210423 was not as obvious as those cells treated with
RO-90-7501. However, we hypothesized that this may have
been due to differences in fluorescence emission of RO-90-
7501 and MRT00210423 or a difference in the association
of the compounds with chromatin. Treatment of cells with
DMSO did not result in the ability to visualize host cell
chromatin in cells (Fig. 5).

Fig. 5. Association of RO-90-7501 and MRT00210423 with host cell
chromatin. HFF cells were treated with decreasing concentrations (10,
1, 0.1 µM, left to right in the figure) of RO-90-7501 or MRT00210423
or the equivalent volume of DMSO and examined by light microscopy.
Brightfield (a–c, g–i, m–o) and UV emission images (d–f, j–l, p–r, s–u) are
shown. In panels s–u images have been manipulated using Photoshop
to increase the brightness of the UV emission from HFF cells treated
with MRT00210423 (panels p–r).

To confirm that our compounds interacted with DNA in
the cell and not another factor in the cell nuclei, we also
tested whether RO-90-7501 and MRT00210423 could associate with DNA outside of the cell. We have been unable
to separate HCMV DNA from cellular DNA in infected
cell lysate or recover high concentrations of intact HCMV
genomes from preparations of HCMV virions (both data not
8
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shown). Moreover, the size (over 230 kbp) and complexity
of the HCMV genome meant that HCMV genomes could
not be easily manipulated in biochemical assays. Therefore,
for convenience, we assayed the ability of RO-90-7501 and
MRT00210423 to interact with linear plasmid DNA (Fig. 6).

putative binding site in its genome, compared to the AD169
genome (listed in Table S8).
Linear plasmid DNA was introduced into an agarose gel
containing either RO-90-7501 or MRT00210423 using
electrophoresis (Fig. 6c, d, respectively). Upon exposure
of the gel to UV light, a DNA band corresponding to the
expected molecular weight of the linear plasmid DNA was
observed in both experiments, suggesting that RO-90-
7501 and MRT00210423 were associated with plasmid
DNA within the agarose gel. Again, we noted that visualization of DNA in the presence of MRT00210423 was
less obvious than in the experiment using RO-90-7501.
Incorporation of a volume of DMSO equivalent to that
used in the aforementioned experiment into agarose gels
did not result in the visualization of any DNA species
(data not shown). Together, the data shown in Figs 5 and
6 confirmed that RO-90-7501 and MRT00210423 could
associate with DNA.

Biochemical studies of Hoechst 33258 in interaction with
DNA have identified canonical DNA sequences to which
bisbenzimide compounds are likely to preferentially bind
[40, 45]. Further analysis of Hoechst 33258 binding to DNA
revealed that bisbenzimide compounds are likely to have
different affinities for these canonical DNA binding sites in
cells [46]. In order of greatest to lowest affinity, bisbenzimide compounds are likely to bind to the canonical DNA
sequences: AAATT, ATTTT, AATAA, TATA, TTAATG,
GTTTAT and TTTCT [46]. To test compound binding to
DNA we used a plasmid (pUC19) that contained several of
the aforementioned sequences (Fig. 6a). We noted that these
sequences are present in high quantity in the sequence of
the HCMV AD169 (Fig. 6b and listed in Table S7). Also, the
HCMV Merlin genome had a near identical number of each

To investigate the relationship between the ability of our
compounds to bind DNA and anti-HCMV effects, we
generated two further compounds, MRT00210426 and
MRT00210427, which lacked either of the amine groups
that were probably required for binding of bisbenzimide
compounds to DNA [40] (Fig. 7, the methyl groups substituted for amine groups highlighted in red in MRT00210426
and MRT00210427) and studied the ability of these
compounds to inhibit HCMV replication in virus replication
assays (Fig. 7). Compared to treatment of cells with DMSO,
we found that neither MRT00210426 nor MRT00210427
had any obvious anti-HCMV effect, whereas MRT00210423
demonstrated an anti-HCMV effect similar to that shown
in Fig. 3. This indicated that an association of bisbenzimide
compounds with DNA was necessary for anti-
HCMV
activity.
To confirm the relationship between anti-HCMV activity and
DNA association of the aforementioned compounds, we then
tested the ability of compounds to associate with DNA in agarose
gels. A DNA molecular weight marker was introduced into an
agarose gel containing compounds indicated in Fig. 7 using
electrophoresis (Fig. S3). Gels were then photographed upon
exposure to UV light, then washed in the UV light-sensitive
DNA stain SYBR Green and again exposed to UV light and
photographed. We found that DNA could be observed in gel
containing MRT00210423 upon initial exposure to UV light.
However, DNA could only be visualized in gels containing
MRT00210426 or MRT00210427 only after the gels were
washed with the DNA stain SYBR Green. These data suggested
that MRT00210423 was associated with DNA in the agarose
gel, but MRT00210426 and MRT00210427 were not. Therefore,
there was a relationship between the ability of compounds to
associate with DNA and anti-HCMV effects. Furthermore, the
binding of our compounds to host cell chromatin (Fig. 5) and
presence of putative bisbenzimide compound binding sites in
the HCMV genome (Fig. 6) suggested that our compounds may
have bound to both host cell chromatin and the HCMV genome
in infected cells.

Fig. 6. Association of RO-90-7501 and MRT00210423 with plasmid DNA.
(a,b) The number of putative compound binding sites in the sequence
of pUC19 and the HCMV AD169 genome, respectively. (c) RO-90-7501
or (d) MRT00210423 was incorporated into agarose gels. Linear pUC19
plasmid (2.6 kbp) and a DNA molecular weight ladder were introduced
into the gel via electrophoresis and the gel was subjected to UV
radiation. In both panels: Lane 1, DNA molecular weight ladder, Lanes
2-onward, two-fold dilution series of 1 µg linear pUC19 plasmid. The
position of pUC19 is indicated with an arrow to the right of each figure.
The position of the 3 kbp marker in Lane 1 is indicated to the left of
each figure.
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Analysis of bisbenzimide action on DNA using
single molecule microscopy
We then attempted to understand what effect RO-90-7501 and
MRT00210423 might have on DNA in HCMV-infected cells. It
has been reported that binding of bisbenzimide compounds to
DNA can result in compaction of DNA via condensation of the
DNA helix [47], which could inhibit any number of biological
processes. We therefore used a single molecule flow-stretching
technique to analyse compaction of a DNA substrate in the
presence of our bisbenzimide compounds. In this assay a bacteriophage lambda genome (which contains 479 bisbenzimide
binding sites) labelled with a quantum dot was placed within a
microfluidic flow cell into which buffer could flow. Using total
internal reflection fluorescence microscopy, the positions of
a quantum dot were tracked in real time while the DNA was
stretched by buffer flow. Quantum dot movement in the presence of flow away or towards the tether could be interpreted
to understand elongation or compaction of the bacteriophage
DNA, respectively (Fig. 8a).

presence of MRT00210423, albeit to apparently a lesser extent.
Therefore, we assayed quantum dot movement at a minimum
concentration of RO-90-7501 in which the quantum dots could
be readily visualized while any change in quantum dot movement was observed. Therefore, we flowed the volume of DMSO
equivalent to 75 µM of either compound resuspended in DMSO
into a flow cell and found that the quantum dot visualized did
not obviously move in the buffer flow (Fig. 8b). However, when
a concentration of 75 µM RO-90-7501 was then flowed into a
flow cell, emission from the quantum dot decreased over time
and the quantum dot moved against the direction of buffer flow
(Fig. 8c). However, when 75 µM MRT00210423 was added to a
flow cell there was no obvious movement of the quantum dot
(Fig. 8d). To ensure that the lack of MRT00210423 compaction in this assay was not due to a concentration-dependent
effect, we repeated the assay adding increasing concentrations of
MRT00201423 up to 1 mM. However, we observed no compaction of DNA in the presence of MRT00210423 at any of the
compound concentrations tested (data not shown).

We conducted a series of preliminary experiments in which
increasing concentrations of RO-90-7501 or MRT00210423 were
flowed into a microfluidic flow cell. We found that increasing
concentrations of RO-90-7501 appeared to quench emission
from the quantum dots used. The same was found in the

Therefore, RO-90-7501 was able to compact DNA in this assay,
whereas MRT00210423 did not. This suggested that compaction of DNA in HCMV-infected cells was not obligatory for
anti-HCMV effects and binding of compounds to DNA alone
was sufficient for our compounds to exert anti-HCMV effects.

Fig. 7. Investigation of anti-HCMV activity of MRT00210423 analogues and their association with DNA. (a) HFF cells were infected with
HCMV strain AD169 (m.o.i. 1) in the presence of the compounds indicated in the figure (1 µM) or an equivalent volume of DMSO. At 96 h
post-infection virus titre (p.f.u. ml–1) from these infections was determined. The data points from three independent experiments are
shown. The columns and error bars represent the mean and sd, respectively, of those data points. The structures of the bisbenzimide
compounds examined are shown to the right of the figure. The methyl groups substituted for amine groups are highlighted in red in
MRT00210426 and MRT00210427.
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Fig. 8. Single molecule imaging of a quantum dot in the presence of RO-90-7501 or MRT00210423. A schematic of the experiment is
shown in (a). A microscopy flow cell containing bacteriophage lambda DNA conjugated with a quantum dot was prepared as described
in the Methods. Buffer containing (b) a volume of DMSO equivalent to 75 µM or either compound (c) 75 µM RO-90-7501 or (d) 75 µM
MRT00210423 was flowed into the microscopy flow cell and movement of the quantum dot was recorded using a total internal reflection
fluorescence microscope. Kymograph panels (b)–(d) show sequential images of the quantum dot in buffer containing either DMSO, RO-
90-7501 or MRT00210423 over time. The time frame of the images and the distance are represented with horizontal and vertical bars,
respectively, in each panel. The direction of the buffer flowing into the microscopy cell is shown with an arrow. In (c) arrows are used to
shown the position of the quantum dot.

acted. A hallmark of HCMV replication is the production
of proteins via a transcriptional cascade of immediate-
early, early and late transcription. Using western blotting,
we assayed the production of proteins representative of all
three classes of viral transcription [HCMV transcriptional
transactivators IE1/IE2 representing proteins produced via

Investigation of HCMV replication in HCMV-infected
cells treated with bisbenzimide compounds
We then sought to understand how RO-
90-
7501 and
MRT00210423 inhibited HCMV replication in infected cells.
First, we investigated HCMV protein production to understand at what point in HCMV replication our compounds
11
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Fig. 9. Production of HCMV proteins, DNA and capsids in the presence of bisbenzimide compounds. (a) HFF cells were infected with
HCMV strain AD169 and treated with the concentrations of RO-90-7501, MRT00210423 (both in 2-fold dilution series starting at 10 µM)
or the corresponding volumes of DMSO. Cell lysates were prepared for western blotting at 72 h post-infection. Western blotting was
used to detect viral (IE1/IE2, UL57 and pp28) and cellular (β-actin) proteins in infected cells treated with either DMSO (lanes 2 and
5), RO-90-7501 (lanes 3 and 6) or MRT00210423 (lanes 4 and 7). Uninfected cells were harvested for analysis at the time of infection
(lane 1). Proteins recognized by the antibodies used are indicated to the right of each figure. The positions of molecular mass markers
(kDa) are indicated to the left of each figure. Blots for IE1/IE2 and UL57 or pp28 or UL86 were performed on separate gels. (b) Viral
DNA synthesis was determined by quantitative real-time PCR analysis of DNA prepared from infected HFF cell lysate (AD169, m.o.i.
1, in the presence of 1 or 10 µM compound or the equivalent volume of DMSO) prepared at the time points indicated in the figure. The
amount of viral DNA detected was represented as copies of the viral gene UL83 per copy of the cellular adipsin gene. The data points
from three independent experiments are shown. The columns and error bars represent the mean and sd, respectively, of those data
points. Statistical significance was assayed using an unpaired t-test and two-tailed P values are shown in the figure. The fold difference
between the values of the mean data is also noted above the figure.
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immediate-early transcription, HCMV DNA binding protein
UL57 representing proteins produced via early transcription,
HCMV virion protein pp28 (tegument protein) and UL86
(major capsid protein) representing proteins produced via late
transcription] in the presence of either DMSO, RO-90-7501
or MRT00210423 (Fig. 9a). We found no obvious differences
in the production of any viral protein in the presence of 1 µM
RO-90-7501 or MRT00210423, compared to viral protein
production in the presence of DMSO. However, compared to
viral protein production in the presence of DMSO, there was a
decrease in expression of some viral proteins in the presence
of 10 µM RO-90-7501 and/or MRT00210423.

capsids. To investigate this, we use electron microscopy of
cells infected with HCMV in the presence of either DMSO
or 1 or 10 µM of our compounds. We counted the number of
each of the three capsid forms that can be found in HCMV-
infected nuclei (A capsids, non-productive forms thought
to result from failed packaging of viral genomes; B capsids,
productive intermediates that contain a scaffolding protein;
and C capsids, assembled forms in which the scaffolding
protein has been removed and replaced with viral DNA)
under each condition (Fig. 10). We anticipated that the presence of our compounds might alter the ratio of B (empty)
to C (DNA-containing) capsids found in infected nuclei,
indicating a defect in genome packaging into capsids. Surprisingly, while we observed large numbers of B capsids and
smaller numbers of A and C capsids in the presence of DMSO,
we found little or no of any capsid type in cells treated with
either compound. Therefore, in the presence of 1 µM of our
compounds, inhibition of HCMV replication was associated
with lack of HCMV capsid production (Fig. 10), but not inhibition of production of HCMV proteins analysed (including
the major capsid protein UL86, Fig. 9a) or inhibition of viral
DNA synthesis (Fig. 9b). However in the presence of 10 µM
of our compounds, inhibition of HCMV capsid production
(Fig. 10) may have contributed to inhibition of HCMV replication and was associated with inhibition of production of
HCMV proteins analysed (including the major capsid protein
UL86, Fig. 9a) and viral DNA synthesis (Fig. 9b).

We then assayed synthesis of HCMV DNA using a quantitative PCR methodology (Fig. 9b). We assayed the number of
viral DNA sequences compared to the number of a cellular
DNA sequence that could be found in HCMV infected cells
treated with either DMSO, RO-90-7501 or MRT00210423 (1
or 10 µM) at immediate-early (24 h post-infection) and late
(96 h post-infection) time points. Compared to viral DNA
synthesis in the presence of DMSO, we found that the presence of 1 µM RO-90-7501 or MRT00210423 had little effect
on viral DNA synthesis, whereas the presence of 10 µM
RO-90-7501 or MRT00210423 had a greater effect on viral
DNA synthesis (Fig. 9b).
Therefore, the presence of 10 µM RO-
90-
7501 or
MRT00210423 was sufficient to inhibit HCMV replication,
HCMV protein production and DNA synthesis (Figs 4 and 9).
However, the presence of 1 µM RO-90-7501 or MRT00210423
was sufficient to inhibit HCMV replication (Fig. 4), but was
not sufficient to obviously inhibit either viral protein production or viral DNA synthesis (Fig. 9). Therefore, we speculated that there was a mechanism by which our compounds
inhibited HCMV replication that did not involve inhibition
of HCMV protein production or DNA synthesis. Packaging
of nascent viral DNA into capsids in the nucleus is essential
for HCMV replication. We hypothesized that our compounds
may have interacted with newly synthesized HCMV DNA
in the nucleus and prevented HCMV DNA packaging into

DISCUSSION
We sought to increase the number of compounds available for
inhibition of HCMV replication by screening collections of
bioactive compounds. Our screening experiments identified
a number of compounds not previously reported to inhibit
HCMV replication. We chose to study RO-90-7501, whose
mechanism of action was likely to be different from known
anti-HCMV compounds. A key step in our studies was to
discover an analogue of RO-90-7501, MRT00210423, which
we found had greater anti-HCMV activity than RO-90-7501.
We found that both RO-90-7501 and MRT00210423 had efficient anti-HCMV activity, with no obvious cellular toxicity,
and that the antiviral activity of the compounds was probably
due to their ability to interact with DNA. Interestingly, we
found that RO-90-7501 and MRT00210423 had different
effects on DNA. Surprisingly, we observed an association
between the presence of compounds in infected cells and
inhibition of HCMV capsid production.
We considered why MRT00210423 had greater anti-HCMV
activity than RO-90-7501. Based upon an atomic structure of
Hoechst 33258 binding to DNA, we reasoned it was possible that
MRT00210423 may have had a greater ability to access the minor
groove of DNA compared to RO-90-7501. The fit of Hoechst
33258 into the minor grove of the DNA was reported to be very
close-fitting, with Hoechst 33258 occupying the entire volume
of the DNA minor groove [40]. Binding of Hoechst 33258 to
DNA [40] involved a twist in the Hoechst 33258 structure, and
the arrangement of groups that comprise Hoechst 33258 was

Fig. 10. Production of HCMV capsids in the presence of bisbenzimide
compounds. Infected cells from three independent experiments [HFF
cells infected with AD169 (m.o.i. 1) for 96 h in the presence of 1 or 10 µM
of either compound, or the equivalent volume of DMSO] were combined
and prepared for analysis by electron microscopy. In each condition, the
number of A, B and C capsids in 10 nucleus profiles selected at random
were counted. Only nuclei where the entire area of the nuclei could be
visualized were counted.
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within which HCMV DNA synthesis occurs [48]. Rather, we
propose that binding of our compounds to chromatin may
have affected the production of one or many cellular factors
required for HCMV replication. Of course, it is possible
that the anti-HCMV effects of our compounds were due to
compound binding to both viral DNA and chromatin. We
considered if a mechanism other than compound binding
to DNA was responsible for anti-HCMV effects. It should
be noted that RO-90-7501 has been reported to enhance
transcription from the β-IFN promoter upon induction of
transcription using poly I:C [49]. However, we found no
evidence for the ability of RO-90-7501 to enhance β-IFN
production in HCMV-infected cells (data not shown) and the
aforementioned work did not investigate what, if any, effects
interaction of RO-90-7501 with chromatin had on enhancing
transcription from the β-IFN promoter [49].

not co-planar. Specifically, there was a small angle between the
phenoic ring and the first benzimidazole group and a much
larger angle between the two consecutive benzimidazole groups
of the compound. The piperazine group was almost co-planar
with the neighbouring benzimidazole group. Together, these
data inferred that Hoechst 33258 had to be fitted into the minor
groove of DNA [40]. Therefore, we propose that removal of the
terminal amine groups from RO-90-7501 allowed a greater flexibility between the groups that comprise MRT00210423 and
allowed a more efficient fit of MRT00210423 into the minor
DNA groove and, thus, easier binding to DNA of MRT00210423
compared to RO-90-7501.
It was also possible that there were differences in metabolism of RO-90-7501 and MRT00210423 within the cell that
resulted in differences in anti-HCMV activity between the two
compounds. However, the structure of the two compounds
was similar. Therefore, it was not obvious what these differences in metabolism might have been.

It is also interesting to consider the mechanistic details of how
compound binding to DNA resulted in anti-HCMV effects.
We hypothesized that, like other bisbenzimide compounds
[47], binding of our compounds to DNA would result in DNA
compaction. DNA compaction could have multiple effects on
DNA function. However, we found compaction of DNA in the
presence of RO-90-7501, but not MRT00210423. Therefore,
compaction of DNA for anti-HCMV effects was non-obligatory
and binding of compounds to DNA alone may have been sufficient for anti-HCMV effects.

At a low concentration of our compounds we observed an
association between inhibition of HCMV replication and a lack
of HCMV capsid production. At present, it is unknown what
molecular mechanisms our compounds use to prevent HCMV
capsid production. Indeed, it is unclear or unknown how many
aspects of capsid formation take place, including what viral and
cellular factors are required for capsid formation and how these
factors are localized and organized in infected cell nuclei. It is
possible that our compounds had effects on one or several viral
and cellular factors required for capsid formation. Furthermore,
at a high concentration of our compounds we also found inhibition of HCMV capsid production. However, this could have been
linked to defects we observed in HCMV protein production and
viral DNA synthesis in the presence of a high concentration of
our compounds. It is unknown if at a high concentration our
compounds act on gene expression or protein production of
the viral factors assayed in our experiments. That said, as we see
efficient inhibition of HCMV replication at a low concentration
of our compounds, investigation of our compounds at a high
concentration is not a priority and future work should focus
on the surprising observation that links inhibition of HCMV
replication with lack of capsid production.

That said, RO-90-7501 and MRT00210423 could be useful tools
in biochemical studies of DNA compaction and its biological
effects. It is possible that DNA compaction by RO-90-7501
resulted in the formation of non-specific structures in DNA
and/or loop formation by bridging two different segments of
a DNA. Looping of DNA was consistent with the relatively
long distance travelled by DNA in our single molecule DNA
stretching experiments in the presence of RO-90-7501. The
underlying mechanisms of DNA looping are largely unknown,
but important for essential biological processes. Comparing
how our compounds bind to DNA and how they have different
effects could further our understanding of DNA function in
the cell.
For future development of compounds for clinical use it may
be necessary to find compounds related to RO-90-7501 and
MRT00210423 that bind preferentially to HCMV genomes
compared to host cell chromatin. Bisbenzimide compounds
are amenable to a range of medicinal chemistry approaches
(for examples see references [50–55]). These could lead to
identification of analogues of our compounds that preferentially
bind HCMV genomes or the conjugation of our compounds to
DNA-binding proteins to target the compound to HCMV DNA.

We hypothesized that our compounds would interact with
HCMV DNA. However, at a low concentration of our
compounds we observed little or no defect in HCMV DNA
synthesis or production of those HCMV proteins analysed.
This might suggest that our compounds did not act directly
on HCMV DNA, but we cannot exclude the possibility that
compound binding to the viral genome affected production
of capsids via an as yet unknown mechanism. Interestingly,
we have found obvious interaction of both compounds with
chromatin in uninfected cells. Therefore, it was possible
that binding of our compounds to cellular chromatin was
required for anti-HCMV effects. As production of those
HCMV proteins analysed and DNA synthesis were not obviously compromised by our compounds, it is unlikely that
the interaction of our compounds with chromatin affected
the formation of nuclear HCMV replication compartments,

That said, several factors support further development of
RO-90-7501 or MRT00210423 as anti-HCMV compounds.
Current anti-HCMV therapy can be limited by drug resistance [7–12]. As yet, we have not been able to generate HCMV
viruses resistant to either RO-90-7501 or MRT00210423 (data
not shown). Plus, as mentioned above, it has been reported that
administration of bisbenzimide compounds has had no serious
adverse effects in murine model experiments and clinical trials
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in humans [42, 43]. Finally, RO-90-7501 and MRT00210423 or
related compounds could have broad antiviral activity, as it has
been demonstrated that bisbenzimide compounds have antiviral
activity against poxviruses [41] and RO-90-7501 can inhibit
replication of vesicular stomatitis virus [49], a model virus for
many important Rhabdoviruses affecting human health.
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